The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Denufosol tetrasodium (INS37217) Intravitreal Injection may provide clinical benefit in treatment of uveitis associated macular edema (UME) by reducing retinal thickness as measured by OCT and possibly enabling recovery of vision loss associated with UME. Denufosol tetrasodium may also reverse the fluid accumulation of UME.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Have anterior uveitis, intermediate uveitis, posterior uveitis or panuveitis in at least one eye
Have persistent macular edema and uveitis whose conditions are stable
Have no change in medication regimen for at least 3 months prior to randomization if currently taking medications such as immunosuppressive or anti-inflammatory agents; steroidal or non-steroidal agents (drops, oral or injected)
Have an OCT scan with a qualifying retinal thickness in the study eye
Have evidence of macular edema on OCT scan
Have at lease one eligible eye to be treated in the study based on visual acuity.
Have proliferative vitreoretinopathy greater than grade B
Have subretinal or vitreous hemorrhage, corneal opacity, or other conditions, which limit the view of the retina or obscure FA
Have uncontrollable elevated IOP, advanced, previous filtration surgery, or any current evidence of endophthalmitis in the study eye
Have ocular disorders in the study eye that may confound interpretation of study results
Have had cataract surgery in the study eye within 3 months, YAG laser capsulotomy within the past 1 month, or any other intraocular surgery within the past 90 days
Have pre-operative spherical equivalent refractive error of more than -10 diopters of myopia in the study eye
Have had any intravitreal or periocular injection or corticosteroids in the study eye during the 3 months prior to screening
Have any ocular implant device for the delivery of therapeutic agents to the eye
Be taking any excluded medications that could obscure or confound study results